Study how early breast cancer responds on imaging and under a microscope
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent.
- You have invasive breast cancer that is either triple-negative, HER2-positive, or high-risk hormone (estrogen) positive.
- Your tumor is at least 2 centimeters (about 0.8 inches) by exam or ultrasound, on at least one side.
- Your health and blood counts are strong enough for chemotherapy-type treatment (specific lab thresholds).
- Your heart function is good enough for the planned cancer medicines (measured by echocardiogram or MUGA).
- You are not pregnant or breastfeeding, and you can use non-hormonal birth control during treatment if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.